To evaluate palatability (primary objective) and perceived satiating effects (secondary objective) of ONS prototypes containing both WPC and MPC and to compare these with palatability and perceived satiating effects of commercially available ONS…
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
geen
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Palatability (liking) of the ONS products will be evaluated with an 11-point
categorical scale ranging from not like at all, to like very much. Each product
will be evaluated for overall liking, liking of taste, liking of sweetness,
liking of creamy flavour, liking of texture, and liking of aftertaste. In
addition, 5-point just-about-right scales (JAR) are used to evaluate the
appropriateness of the thickness and the intensity of the taste, sweetness,
creamy flavour, and aftertaste. Palatability questions will be completed after
consumption of one sip and after a full portion.
Secondary outcome
Secondary parameters include perceived satiety (prior to consumption, directly
after consumption of a full portion and at 1 and 2 hours post consumption) and
drivers of liking (i.e. sensory aspects, emotions and functional attributes
associated with the product).
Background summary
ONS products ae prescribed in case of malnutrition that cannot be treated by
with regular foods. In general, intake of ONS is lower than prescribed amounts.
The main sensory related reasons for a low intake of oral nutritional
supplements (ONS) products have been reported as, disliking the flavour and
unpleasant satiating properties. In collaboration with commercial partners
Fonterra developed two prototypes of ONS based on a combination of milk protein
concentrate (MPC) and whey protein concentrate (WPC). Due to the
characteristics of the WPC, the prototype products are easily digested and have
a low viscosity which facilitates consumption and are expected to be less
satiating as compared to commercially available products that contain MPC only.
Furthermore the flavour is optimized to increase palatability of the product.
If both issues are true, compliance with ONS may be improved.
Study objective
To evaluate palatability (primary objective) and perceived satiating effects
(secondary objective) of ONS prototypes containing both WPC and MPC and to
compare these with palatability and perceived satiating effects of commercially
available ONS products containing MPC only. In addition, we aim to investigate
drivers of liking, i.e. sensory aspects, emotions and functional attributes, of
ONS products.
Study design
The study is a single-blind intervention with a within-subjects design.
Participants will visit the research facilities 8 times to evaluate different
ONS products. On each test day a single prodct is evaluated using
questionnaires. There are 2 test days per week with at least one day in between
test days.
Intervention
In this intervention study we will evaluate a full portion of 8 different
vanilla flavoured ONS products (one product per test day, with at least 1 day
in between test days).
Products include two ONS prototypes containing 50% WPC, 50% MPC (Fonterra) and
six commercially available ONS products containing MPC only. Calorie content of
the served portion will be comparable (300-320 kcal), but protein density
(12-20g protein per portion) will differ between products. The products will be
given in randomised order.
Study burden and risks
There are minor risks for the participants of this study. There are no direct
benefits for the participants. Study participants in our study are not the
target group of ONS products, however as undernourished older adults are a
vulnerable population it was decided to first evaluate the products in a
healthy adult population. Data will be collected through questionnaires and no
other invasive measurements are included. Study participants will invest
approximately 20 hours during the intervention and need to visit the research
facility on 8 occasions (2 times a week during 4 weeks). The 2 ONS prototype
products are safe for consumption and the 6 other ONS products are commercially
available.
Eurocentre 2, Barbara Strozzilaan 356 - 360
Amsterdam 1083 HN
NL
Eurocentre 2, Barbara Strozzilaan 356 - 360
Amsterdam 1083 HN
NL
Listed location countries
Age
Inclusion criteria
* Age >65 years or over
* Apparently healthy
* Living independently
Exclusion criteria
* Allergies to soy, dairy or gluten
* Following a specific diet
* BMI>30
* Reduced kidney function
* Suffering from Alzheimer*s disease, Dementia, Parkinson*s Disease, Cancer,
Kidney Disease or Diabetes
* Suffering from Dysphagia
* Already using oral nutritional supplements
* Receiving any medical treatment that is known to reduce the taste or sense of
smell
* Current smokers
* Participation in another clinical trial at the same time
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL70308.081.19 |
| Other | nog niet ontvangen |